Dupilumab in CRSsNP
Completed · Phase 2 · NCT04678856
Conditions: Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
At a glance
- Research payments reported, 2025
- $18,403
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 71
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab SAR231893 (drug), Placebo (drug)
- Dates
- Started 2020-12-02; completion 2024-01-29
- Results posted
- Yes
Primary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: * To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on CT scan and sinus total symptom score (sTSS) compared to placebo * To evaluate the safety and tolerability of dupilumab in CRSsNP patients compared to placebo * To evaluate the pharmacokinetics (PK) of dupilumab in CRSsNP patients compared to placebo * Assessment of immunogenicity to dupilumab over time compared to placebo
From ClinicalTrials.gov, last updated 2026-07-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $18,403 in research payments for this study in 2025 (3 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Eastern Virginia Medical School Department of Internal Medicine $18,403
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.